• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

Introduction to 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid (CAS No. 19692-02-5)

6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid (CAS No. 19692-02-5) is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, holds potential applications in the development of novel therapeutic agents. The compound's structure includes a cyclohexene ring substituted with a thiazole carbamoyl group, which contributes to its chemical and biological properties.

The chemical structure of 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid is defined by its molecular formula C₁₃H₁₃N₃O₃S and a molecular weight of 287.32 g/mol. The presence of the thiazole ring and the carboxylic acid functional group imparts specific reactivity and solubility characteristics, making it an interesting candidate for various chemical reactions and biological studies.

In recent years, there has been a growing interest in the development of small molecules with anti-inflammatory and anti-cancer properties. 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid has been investigated for its potential as a lead compound in these areas. Studies have shown that this compound exhibits significant inhibitory effects on key enzymes involved in inflammatory pathways, such as cyclooxygenase (COX) and lipoxygenase (LOX). These findings suggest that it could be a valuable starting point for the design of more potent and selective anti-inflammatory drugs.

Beyond its anti-inflammatory properties, 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid has also shown promise in cancer research. Preclinical studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action appears to involve the modulation of signaling pathways that regulate cell survival and proliferation. Specifically, it has been observed to inhibit the activation of nuclear factor-kappa B (NF-κB), a transcription factor known to play a crucial role in cancer progression.

The pharmacokinetic properties of 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid have also been studied to assess its suitability as a therapeutic agent. Research has indicated that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. The compound is well-absorbed orally and shows good bioavailability, which is essential for its potential use as an oral medication. Additionally, it demonstrates low toxicity in animal models, further supporting its safety profile.

In the context of drug discovery and development, the synthesis of 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid is an important aspect to consider. Various synthetic routes have been reported in the literature, each with its own advantages and limitations. One common approach involves the reaction of 6-bromocyclohexa-3-enecarboxylic acid with thiazole derivatives under appropriate conditions to form the desired product. The choice of synthetic method can significantly impact the yield and purity of the final compound, which are critical factors in pharmaceutical development.

The structural diversity within the class of compounds related to 6-(1,3-thiazol-2-ylcarbamoyl)cyclohex-3-ene-1-carboxylic acid offers opportunities for further optimization and derivatization. By modifying substituents on the cyclohexene ring or the thiazole moiety, researchers can explore new derivatives with enhanced biological activity or improved pharmacological properties. This approach aligns with modern drug discovery strategies that emphasize structure-based design and high-throughput screening techniques.

In conclusion, 6-(1,3-thiazol-2-ylcarbamoyl)cyclohexaene carboxylic acid (CAS No. 19692-02-5) represents a promising compound with potential applications in both anti-inflammatory and anti-cancer therapies. Its unique chemical structure and favorable biological properties make it an attractive candidate for further investigation and development. As research in this area continues to advance, it is likely that new insights into the mechanisms of action and therapeutic potential of this compound will emerge, paving the way for innovative treatments in medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)